Showing results (151-160 of 211) with videos related to

Sort By:
Pageof 22
Journal of Clinical Medicine|November 20, 2020
A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after DiscontinuationMatteo Dragani, Giovanna Rege Cambrin, Paola Berchialla, et al.
American Journal of Hematology|August 30, 2023
Risk of progression in chronic phase-chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR-PRO studyGiovanni Paolo Maria Zambrotta, Franck E Nicolini, Sarit Assouline, et al.
Annals of Hematology|October 4, 2017
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter seriesAlessandra Iurlo, Sara Galimberti, Elisabetta Abruzzese, et al.
Leukemia Research|December 9, 2015
Dasatinib first-line: Multicentric Italian experience outside clinical trialsMassimo Breccia, Fabio Stagno, Luigiana Luciano, et al.
Hematological Oncology|March 21, 2019
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chartGiovanni Caocci, Olga Mulas, Elisabetta Abruzzese, et al.
Lancet (London, England)|January 28, 2023
Momelotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 studySrdan Verstovsek, Aaron T Gerds, Alessandro M Vannucchi, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 18, 2024
The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment PlanMichele Malagola, Alessandra Iurlo, Cristina Bucelli, et al.
American Journal of Hematology|June 15, 2024
Long-term pharmacodynamic and clinical effects of twice- versus once-daily low-dose aspirin in essential thrombocythemia: The ARES trialBianca Rocca, Alberto Tosetto, Giovanna Petrucci, et al.
Hematological Oncology|April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world dataFrancesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Blood|April 9, 2020
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemiaBianca Rocca, Alberto Tosetto, Silvia Betti, et al.
Pageof 22